Ross Moat - Apr 10, 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
CHIEF COMMERCIAL OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
Apr 10, 2023
Transactions value $
-$14,491
Form type
4
Date filed
4/11/2023, 05:06 PM
Previous filing
Apr 3, 2023
Next filing
Sep 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise +2.48K +21.67% 13.9K Apr 10, 2023 Direct F1
transaction KNSA Class A Common Share Tax liability -$14.5K -1.35K -9.73% $10.71 12.6K Apr 10, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Options Exercise $0 +2.48K +50% $0.00 7.43K Apr 10, 2023 Class A Common Share 2.48K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.